Date published: 2025-10-11

00800 4573 8000

SCBT Portrait Logo
Seach Input

C18orf19 Inhibidores

The chemical class of "C18orf1 Inhibitors" represents a group of diverse compounds that indirectly influence the activity of the protein encoded by the C18orf1 gene. This collection exemplifies a multifaceted approach to protein modulation, emphasizing the use of various biochemical pathways and cellular processes to impact protein function indirectly. The variety of mechanisms employed by these compounds highlights the complex nature of protein regulation and the potential for modulating protein activity through targeting related cellular pathways.

Among the compounds in this class, agents like Doxorubicin and Cisplatin demonstrate the impact of DNA interaction and damage on protein activity. Doxorubicin, an anthracycline antibiotic, affects DNA replication and repair mechanisms, potentially altering the cellular context and thus influencing the activity of C18orf1. Cisplatin's ability to induce DNA crosslinking exemplifies how DNA damage can lead to changes in protein activity. These compounds underline the role of DNA integrity and repair processes in the regulation of protein functions.

Etoposide and 5-Fluorouracil, affecting topoisomerase activity and nucleotide synthesis, respectively, further illustrate the intricate relationship between DNA repair processes and protein regulation. By influencing these key cellular functions, these compounds can potentially modulate the activity of proteins involved in various pathways, including C18orf1.

Kinase inhibitors such as Sorafenib, by targeting multiple signaling pathways, reflect the complex network of intracellular signaling and its impact on protein activities. Sorafenib demonstrates the potential for broad effects on protein functions, including those related to C18orf1, by modulating key signaling networks within the cell.

The inclusion of immunomodulatory drugs like Tacrolimus and Fingolimod in this class represents another facet of protein modulation. Tacrolimus, through its inhibition of calcineurin, and Fingolimod, by modulating sphingosine 1-phosphate receptor signaling, illustrate the interconnected nature of immune signaling and protein regulation. These compounds showcase the potential of targeting immune responses to indirectly regulate proteins involved in various cellular functions.

Furthermore, the presence of compounds like Curcumin, Methotrexate, and Hydroxychloroquine highlights the role of modulating metabolic, inflammatory, and immune pathways in influencing protein activity. Curcumin's anti-inflammatory and antioxidant properties, Methotrexate's impact on folate metabolism, and Hydroxychloroquine's role in autoimmune disease management elucidate the varied approaches that can be employed to indirectly modulate protein function.

In summary, the "C18orf1 Inhibitors" class represents a comprehensive approach to modulating protein activity, emphasizing the potential of leveraging various biochemical pathways and cellular processes. This class not only sheds light on the complex regulation of proteins like C18orf1 but also underscores the broader implications of such modulation in cellular physiology. As research continues to evolve, a deeper understanding of these biochemical interactions is expected to emerge, offering new perspectives on protein regulation. This approach exemplifies the sophistication of current scientific understanding and the ongoing efforts to develop more effective strategies for modulating protein activity in complex biological systems.

VER TAMBIÉN ....

Items 1 to 10 of 21 total

Mostrar:

Nombre del productoNÚMERO DE CAS #Número de catálogoCantidadPrecioMENCIONESClasificación

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

Inhibidor de PI3K que impide la fosforilación de Akt, lo que conduce a la regulación a la baja de FAM210A.

Doxorubicin

23214-92-8sc-280681
sc-280681A
1 mg
5 mg
$173.00
$418.00
43
(3)

La doxorrubicina, un antibiótico antraciclínico, puede afectar a la replicación y reparación del ADN, influyendo potencialmente en la actividad de C18orf1.

Cisplatin

15663-27-1sc-200896
sc-200896A
100 mg
500 mg
$76.00
$216.00
101
(4)

El cisplatino, un fármaco basado en el platino, puede inducir el entrecruzamiento del ADN, afectando potencialmente a la actividad de C18orf1.

Etoposide (VP-16)

33419-42-0sc-3512B
sc-3512
sc-3512A
10 mg
100 mg
500 mg
$32.00
$170.00
$385.00
63
(1)

El etopósido, un inhibidor de la topoisomerasa, puede afectar a los mecanismos de reparación del ADN, influyendo potencialmente en la actividad de C18orf1.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$150.00
$388.00
113
(4)

Inhibidor de la proteína cinasa, inhibe varias cinasas responsables de la fosforilación de FAM210A.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

Inhibidor de JNK; bloquea eventos de fosforilación esenciales para la migración celular mediada por FAM210A.

Fluorouracil

51-21-8sc-29060
sc-29060A
1 g
5 g
$36.00
$149.00
11
(1)

El 5-Fluorouracilo, un análogo de la pirimidina, puede influir en la síntesis de nucleótidos, afectando potencialmente a la actividad de C18orf1.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

Inhibidor de ROCK; afecta a la dinámica de la actina y regula a la baja FAM210A.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

El metotrexato, un inhibidor de la dihidrofolato reductasa, puede afectar al metabolismo del folato, influyendo potencialmente en la actividad de C18orf1.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

El sorafenib, un inhibidor de la cinasa, puede afectar a múltiples vías de señalización, influyendo potencialmente en la actividad de C18orf1.